Owlet, Inc. (OWLT) - 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers Owlet, Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Owlet is a pediatric health platform offering FDA-cleared wearable monitors (Dream Sock, BabySat) and video monitors (Dream Sight) for home use. The company operates as a single segment, transitioning from a hardware-centric model to a comprehensive platform including the Owlet360 subscription service. As of December 31, 2025, the company had 108 full-time employees and distributed products in over 30 countries.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | $105.7 million | $78.1 million | +35.4% |
| Gross Profit | $53.5 million | $39.3 million | +36.2% |
| Gross Margin | 50.6% | 50.4% | +20 bps |
| Operating Loss | $(8.3) million | $(20.2) million | Improved |
| Net Loss | $(39.7) million | $(12.5) million | Widened |
| Adjusted EBITDA | $2.0 million | $(1.8) million | Positive for first time |
| Cash and Equivalents | $35.5 million | $20.2 million | +75.7% |
| Total Debt (Principal) | $13.9 million | $13.8 million | Flat |
| Operating Cash Flow | $(10.8) million | $(11.2) million | Improved |
Note: Net Loss widened primarily due to a $26.6 million non-cash mark-to-market adjustment on common stock warrant liabilities.
Material Changes vs. Prior Period
- Revenue Growth: Driven by increased sales of Dream Sock and Dream Duo products and the launch of the Owlet360 subscription service in January 2025, which reached over 98,000 subscribers by year-end.
- Margin Expansion: Gross margin improved slightly despite tariff headwinds, aided by favorable product mix and fixed cost absorption.
- Expense Management: General and Administrative (G&A) expenses decreased by 13.9% due to the absence of significant litigation settlement costs and impairment charges recognized in 2024. Research and Development (R&D) increased 43.6% due to investments in product development and clinical testing.
- Capital Structure: The company completed a $32.1 million public equity offering in October 2025 and executed a warrant exchange in October 2025, converting significant warrant liabilities into equity.
Guidance, Outlook, and Risks
Outlook and Strategy: Management views 2025 as a year of "Scale and Transformation." The company aims to expand the Owlet360 subscription platform, grow healthcare channels for the BabySat device (currently reimbursed in 37 states via Medicaid and over 250 commercial carriers), and expand internationally, with a commercial launch in India expected in early 2026. Production capacity is being expanded to Mexico in 2026 to mitigate supply chain risks.
Key Risks and Contingencies:
- Internal Controls: The company identified material weaknesses in internal control over financial reporting related to segregation of duties, inventory accounting, debt/equity arrangements, and IT general controls. While one weakness regarding cash flow review was remediated, others remain ongoing.
- Liquidity: The company has a history of losses and negative operating cash flows. It relies on cash reserves and credit facilities (WTI Loan Facility and ABL Line of Credit) to fund operations. A liquidity covenant requires maintaining $4.0 million in liquidity; falling below $9.0 million triggers an EBITDA covenant.
- Supply Chain: Reliance on single-source manufacturers (Benchmark Electronics in Thailand, Aoni in China/Vietnam) and exposure to NAND flash memory shortages and tariffs (10-40% depending on origin) pose significant risks to margins and availability.
- Regulatory: Continued compliance with FDA and international medical device regulations is critical. Failure to maintain clearances or obtain new ones could severely harm the business.
- Legal: Pending final court approval of settlements for securities class actions (Butala and Vargas cases) totaling approximately $5.9 million in liabilities.
Investor Verification Checklist
- Internal Control Remediation: Verify the timeline and effectiveness of remediation plans for the remaining material weaknesses in financial reporting controls.
- Subscription Metrics: Confirm the retention rates and revenue contribution of the Owlet360 subscription service to validate the recurring revenue model.
- Tariff Impact: Assess the actual impact of current and potential future tariffs on the cost of goods sold and gross margins, particularly for products manufactured in Vietnam and Thailand.
- Reimbursement Expansion: Monitor the progress of BabySat insurance reimbursement coverage and adoption rates in healthcare channels.
- Liquidity Covenants: Review quarterly compliance with the ABL Line of Credit liquidity and EBITDA covenants to ensure no risk of default.
- Customer Concentration: Note that the three largest customers represented 66.5% of 2025 revenue; verify the stability of these retail relationships.